{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:35Z","timestamp":1793398235840,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Plasma tryptophan metabolites were measured using liquid chromatography\/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 19 patients with NSCLC had significantly lower levels of tryptophan (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) and xanthurenic acid (<jats:italic>p<\/jats:italic>\u2009=\u20090.032), and a significantly higher level of 3-hydroxyanthranilic acid (3-HAA) (<jats:italic>p<\/jats:italic>\u2009=\u20090.028) compared with the 10 healthy volunteers. The patients achieving objective responses had significantly lower levels of 3-HAA than those who did not (<jats:italic>p<\/jats:italic>\u2009=\u20090.045). Receiver operating characteristic analyses determined that the cutoff value of 3-HAA for objective response was 35.4\u00a0pmol\/mL (sensitivity: 87.5% and specificity: 83.3%). The patients with 3-HAA\u2009&lt;\u200935.4\u00a0pmol\/mL had significantly longer median progression-free survival (7.0\u00a0months) than those without (1.6\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.022).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Tryptophan metabolites may have a potential for predicting the efficacy of ICIs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Registration number<\/jats:title>\n                <jats:p>University Hospital Medical Information Network Clinical Trial Registry 000026140.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-020-02421-8","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T15:03:42Z","timestamp":1591974222000},"page":"418-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-4070","authenticated-orcid":false,"given":"M.","family":"Karayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"2421_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2421_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:1\u201311.","journal-title":"Exp Mol Med"},{"key":"2421_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1178646917691938","volume":"10","author":"AAB Badawy","year":"2017","unstructured":"Badawy AAB. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res. 2017;10:1.","journal-title":"Int J Tryptophan Res"},{"key":"2421_CR4","first-page":"1206","volume":"09","author":"A Takada","year":"2018","unstructured":"Takada A, Shimizu F, Takao T, Masuda J. Measurement of tryptophan metabolites in healthy old men and patients of type 2 diabetes mellitus (T2DM). Food Nutr Sci. 2018;09:1206\u201320.","journal-title":"Food Nutr Sci"},{"key":"2421_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-015-0094-9","volume":"3","author":"YW Moon","year":"2015","unstructured":"Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer. 2015;3:1\u201310.","journal-title":"J Immunother Cancer"},{"key":"2421_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","volume":"37","author":"DH Munn","year":"2016","unstructured":"Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation and tolerance. Trends Immnol. 2016;37:193\u2013207.","journal-title":"Trends Immnol"},{"key":"2421_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.lungcan.2009.05.001","volume":"67","author":"Y Suzuki","year":"2010","unstructured":"Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, et al. Increased serum kynurenine\/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2010;67:361\u20135.","journal-title":"Lung Cancer"},{"key":"2421_CR8","first-page":"761","volume":"10","author":"J Masuda","year":"2019","unstructured":"Masuda J, Karayama M, Suda T, Maekawa M, Shimizu F, Takada A. Effects of gender, age, and clot formation on the measurements of tryptophan metabolites in blood. Food Nutr Sci. 2019;10:761\u201375.","journal-title":"Food Nutr Sci"},{"key":"2421_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.imlet.2008.01.001","volume":"117","author":"AS L\u00f3pez","year":"2008","unstructured":"L\u00f3pez AS, Alegre E, D\u00edaz-Lagares \u00c1, Garc\u00eda-Gir\u00f3n C, Coma MJ, Gonz\u00e1lez \u00c1. Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules indoleamine dioxygenase and HLA-G in macrophages. Immunol Lett. 2008;117:91\u20135.","journal-title":"Immunol Lett"},{"key":"2421_CR10","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1039\/C6FO00187D","volume":"7","author":"K Lee","year":"2016","unstructured":"Lee K, Kwak JH, Pyo S. Inhibition of LPS-induced inflammatory mediators by 3-hydroxyanthranilic acid in macrophages through suppression of PI3K\/NF-\u03baB signaling pathways. Food Funct. 2016;7:3073\u201382.","journal-title":"Food Funct"},{"key":"2421_CR11","first-page":"3","volume":"1","author":"M Berg","year":"2019","unstructured":"Berg M, Polyzos KA, Agardh H, Baumgartner R, Forteza MJ, Kareinen I, et al. 3-Hydroxyanthralinic acid metabolism controls the hepatic srebp\/lipoprotein axis, inhibits inflammasome activation in macrophages, and decreases atherosclerosis in LDLR-\/- Mice. Cardiovasc Res. 2019;1:3.","journal-title":"Cardiovasc Res"},{"key":"2421_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01973","volume":"10","author":"M Gargaro","year":"2019","unstructured":"Gargaro M, Vacca C, Massari S, Scalisi G, Manni G, Mondanelli G, et al. Engagement of nuclear coactivator 7 by 3-hydroxyanthranilic acid enhances activation of aryl hydrocarbon receptor in immunoregulatory dendritic cells. Front Immunol. 2019;10:1\u201314.","journal-title":"Front Immunol"},{"key":"2421_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med. 2013;5:25\u2013129.","journal-title":"Sci Transl Med."},{"key":"2421_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1189\/jlb.3A0315-135R","volume":"99","author":"J Prodinger","year":"2016","unstructured":"Prodinger J, Loacker LJ, Schmidt RLJ, Ratzinger F, Greiner G, Witzeneder N, et al. The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4 + T cells and inhibits c-Myc activation. J Leukoc Biol. 2016;99:583\u201394.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2421_CR15","first-page":"13","volume":"8","author":"E Wirthgen","year":"2018","unstructured":"Wirthgen E, Hoeflich A, Rebl A, G\u00fcnther J. Kynurenic Acid: The Janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions. Front Immunol. 2018;8(1):13\u201340.","journal-title":"Front Immunol"},{"key":"2421_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-20173-y","volume":"8","author":"A Szabo","year":"2018","unstructured":"Szabo A, Gogolak P, Koncz G, Foldvari Z, Pazmandi K, Miltner N, et al. Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset of human dendritic cells. Sci Rep. 2018;8:1\u201312.","journal-title":"Sci Rep"},{"key":"2421_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365.","journal-title":"Lancet"},{"key":"2421_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"2421_CR19","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02421-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02421-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02421-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:07:27Z","timestamp":1623456447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-020-02421-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02421-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"28 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no relevant relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the ethical standards described in the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Hamamatsu University School of Medicine (No. 19-083).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All of the patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}